EndoQuest Robotics closes Series D-2; filing reports $30.745 million sold
EndoQuest Robotics closed its Series D-2; the later Form D reported $30,744,999 sold, which is used instead of the larger offering target.
Why it matters
EndoQuest Robotics closed a Series D-2 financing co-led by Crescent Enterprises and Dr. Fred Moll to advance its pivotal clinical trial, FDA pathway and endoluminal visualization systems.
Evidence notes
- The company explicitly described the Series D-2 financing as successfully closed.
- Crescent Enterprises and Dr. Fred Moll co-led; Puma Venture Capital and UTHealth Houston also participated.
- A subsequent SEC Form D reported the completed amount sold, separate from the larger total offering target.
Company context
EndoQuest Robotics develops a flexible endoluminal surgical robot for procedures performed through the body’s natural orifices. Founded in Houston as ColubrisMX and rebranded in 2022, the company combines steerable endoscopy with robotic instrument control for upper and lower gastrointestinal interventions. Its investigational ELS System is intended to enable precise, scar-free surgery without external incisions.